ArticleBMJ medicine2022
Changes in industry marketing payments to physicians during the covid-19 pandemic: quasi experimental, difference-in-difference study.
Article in BMJ medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review to Explore the Role of Industry and Regulators on Minimally Invasive Aesthetics Education: A Tale of Two Cities.Aesthetic plastic surgery · 2025Pooled it
- How often do oncologists receive industry payments from competing companies?The oncologist · 2026Article
- Direct-to-Physician Marketing and Uptake of Optimal Medical Therapy for Heart Failure With Reduced Ejection Fraction.JACC. Heart failure · 2025Article
- Dissemination of VMAT-2 Inhibitors: A New Class Drug for Tardive Dyskinesia and Huntington Disease.Neurology. Clinical practice · 2025Article
- Trends in enforcement of National Comprehensive Cancer Network financial conflict of interest policy.JNCI cancer spectrum · 2024Article
- Trends in financial payments from industry to US cancer centers, 2014-2021.JNCI cancer spectrum · 2024Article
- Cross-sectional analysis of financial relationships between board certified allergists and the pharmaceutical industry in Japan.BMC medical ethics · 2024Article
- Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States.Gynecologic oncology · 2024Article
- Industry Payments Received by Residents During Training.JAMA network open · 2023Article
- Characterizing industry payments to US teaching hospitals and affiliated physicians: a cross-sectional analysis of the Open Payments datasets from 2016 to 2022.Health affairs scholar · 2023Article
- Facial plating industry payments: An analysis of the open payments database.Laryngoscope investigative otolaryngology · 2023Article
- Trends in Industry Payments to Cardiologists From 2014 to 2019.Circulation. Cardiovascular quality and outcomes · 2023Article
- Trends in Industry Payments to Diabetologists and Endocrinologists in the United States During the COVID-19 Pandemic.Cureus · 2022Article
- Article
- Disparities in Industry Payments Between Orthopaedic Surgery and General Surgery Residents.JB & JS open accessReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Objective: To determine changes in industry marketing payments to physicians due to the covid-19 pandemic. Design: Quasi experimental, difference-in-difference study. Data source: US nationwide database of licensed physicians, the National Plan and Provider Enumeration System, which was linked to a database of industry marketing payments made to physicians, Open Payments. Population: All licensed US physicians from 2018 to 2020 and those who received payments from industry. Main outcome measures: Changes in the value and the number of monthly industry payments physician received before (January-February 2020) and during the pandemic (April-December 2020) were assessed, adjusting for physicians' characteristics (gender and specialty). As the control, data for the same months in 2019 were used. Industry payments by type of payments (eg, meals, travel, consulting fees, speaker compensation, honorariums), were also examined. Results: Among 880 589 US physicians included in this study, 267 463 (30.4%) physicians received a total of 4 117 482 non-research payments with $626 million ($710 per physician; £610; €708) in 2020 (40-44% decrease from $1047m in 2018 and $1115m in 2019). Industry payments decreased significantly in the months of the covid-19 pandemic (adjusted change in the value of -48.4%; 95% confidence interval -50.6 to -46.2; P<0.001; and adjusted change in the number of -47.4%, 95% confidence interval -47.7 to -47.1; P<0.001), particularly for meals and travel fees. No evidence was seen of a decrease in the number of industry payments for consulting and honorariums. A similar pattern was observed across physicians' gender and specialty. Conclusions: Industry payments to physicians, particularly those involving physical interactions such as meals and travel, substantially decreased during the pandemic. How such changes affect prescription practices and the quality of clinical practice in the long term should be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.